Arcus BiosciencesRCUS
RCUS
About: Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Employees: 674
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
234% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 29
5% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $1.03M
0.07% more ownership
Funds ownership: 91.69% [Q4 2024] → 91.76% (+0.07%) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 32
1% less funds holding
Funds holding: 185 [Q4 2024] → 184 (-1) [Q1 2025]
39% less capital invested
Capital invested by funds: $1.25B [Q4 2024] → $763M (-$487M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$13
41%
upside
Avg. target
$18.75
103%
upside
High target
$26
181%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Morgan Stanley Terence Flynn | 138%upside $22 | Overweight Maintained | 9 May 2025 |
Goldman Sachs Salveen Richter | 41%upside $13 | Neutral Maintained | 8 May 2025 |
Wells Fargo Eva Fortea Verdejo | 181%upside $26 | Overweight Maintained | 7 May 2025 |
Barclays Peter Lawson | 52%upside $14 | Overweight Maintained | 23 Apr 2025 |
Financial journalist opinion
Based on 3 articles about RCUS published over the past 30 days
Neutral
Business Wire
4 days ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 8,400 shares of the Company's common stock at an exercise price per share of $9.85, which was the closing price on June 9, 2025, and restri.
Neutral
Business Wire
2 weeks ago
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. “I was very encouraged to see that nearly half of patients had a.
Neutral
Business Wire
2 weeks ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 13,400 shares of the Company's common stock at an exercise price per share of $9.02, which was the closing price on May 23, 2025, and res.
Neutral
Business Wire
1 month ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,250 shares of the Company's common stock at an exercise price per share of $8.53, which was the closing price on May 8, 2025, and re.
Neutral
Seeking Alpha
1 month ago
Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript
Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Pia Eaves - VP, IR Terry Rosen - CEO Richard Markus - CMO Jennifer Jarrett - COO Bob Goeltz - CFO Juan Jaen - President Conference Call Participants Peter Lawson - Barclays Daina Graybosch - Leerink Partners Yigal Nochomovitz - Citigroup Umer Raffat - Evercore Eva Fortea - Wells Fargo Emily Bodnar - HC Wainwright Operator Hello, everyone. And welcome to Arcus Biosciences First Quarter 2025 Earnings and Financial Results Call.
Negative
Zacks Investment Research
1 month ago
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.05 per share a year ago.
Neutral
Business Wire
1 month ago
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers. “Beginning with an oral presentation at ASCO for casdatifan in ccRCC, we expect to report.
Neutral
Business Wire
1 month ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 39,750 shares of the Company's common stock at an exercise price per share of $8.11, which was the closing price on April 23, 2025 and re.
Neutral
Business Wire
1 month ago
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that data from the ARC-20 study will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3, 2025. The oral presentation will highlight the first safety and efficacy data for the ARC-20.
Neutral
Business Wire
1 month ago
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2025. Investors interested in listening to the c.
Charts implemented using Lightweight Charts™